January 21, 2021
Article
The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.
January 19, 2021
A study found patients with acute infection and those with viral rebound after antiretroviral therapy interruption had the highest viral resistance to type 1 interferons.
January 13, 2021
Anal squamous cell carcinoma mortality rate is rising faster than other types of cancer in the United States.
January 05, 2021
While social determinants, stigma about the virus, and continuum of care issues remain challenges to many people with HIV, The IDSA is looking to address these issues with its new guidance.
January 04, 2021
The FDA’s breakthrough designation of cabotegravir along with adaptive strategies being deployed are the biggest stories in HIV prevention this year.
Video
A principal investigator studying dolutegravir/lamivudine discusses its efficacy and potential treatment benefits.
December 31, 2020
A research team recently presented their efforts to integrate machine learning to identify people at high-risk of acquiring HIV.
December 30, 2020
A new article shows that breastfeeding after receiving dolutegravir in late pregnancy contributed relatively little infant plasma exposure but additional prophylaxis was reported among some.
December 29, 2020
The ADVANCE study results at 96 weeks distinguish between the long-term effects of 3 combination regimens for HIV in weight gain and bone density change.
December 28, 2020
Participants in clinical trials of long-acting injectable antiretroviral therapy for HIV describe expectations and experience with the investigational dosage form.
